Drug Type TIL therapy |
Synonyms KSQ 004, KSQ004 |
Target |
Mechanism SOCS1 modulators(suppressor of cytokine signaling 1 modulators), regnase-1 modulators(zinc finger CCCH-type containing 12A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization KSQ Therapeutics, Inc.Startup |
Active Organization KSQ Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |
Colorectal Cancer | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |
Melanoma | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |
Non-Small Cell Lung Cancer | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |
Pancreatic Ductal Adenocarcinoma | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |
Uterine Cervical Cancer | Phase 2 | US | KSQ Therapeutics, Inc.Startup | 21 Nov 2024 |